Arzeda Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$21.5M
- Investors
-
24
Arzeda General Information
Description
Developer of a protein design platform designed to create new proteins and enzymes for industrial and commercial applications. The company offers generative artificial intelligence-based protein design, validation, and manufacturing capabilities, enabling biotechnology, industrial, and consumer goods companies to develop sustainable products with improved performance and production efficiency.
Contact Information
Website
www.arzeda.comCorporate Office
- 3421 Thorndyke Avenue West
- Seattle, WA 98119
- United States
Corporate Office
- 3421 Thorndyke Avenue West
- Seattle, WA 98119
- United States
Arzeda Timeline
Arzeda Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC (Series B) | 01-Dec-2025 | $21.5M | Completed | Generating Revenue | ||
| 12. Later Stage VC | 01-Sep-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B) | 01-Mar-2022 | Completed | Generating Revenue | |||
| 10. Grant | 31-Dec-2021 | Completed | Generating Revenue | |||
| 9. Debt - PPP | 30-Apr-2020 | Completed | Generating Revenue | |||
| 8. Grant | 31-Dec-2018 | Completed | Startup | |||
| 7. Grant | 31-Dec-2017 | Completed | Startup | |||
| 6. Later Stage VC (Series A) | 01-Jul-2017 | Completed | Startup | |||
| 5. Grant | 31-Dec-2015 | $220K | $250K | Completed | Startup | |
| 4. Seed Round | 01-Dec-2014 | $250K | $250K | Completed | Startup |
Arzeda Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-4 | ||||||||
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 1,108,940 | $0.000100 | 8% | $4.55 | $4.55 | 1x | $4.55 | 2.1% |
| Seed | 364,630 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 0.69% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Arzeda Comparisons
Industry
Financing
Details
Arzeda Competitors (13)
One of Arzeda’s 13 competitors is Novonesis, a Corporation company based in Lyngby, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novonesis | Corporation | Lyngby, Denmark | ||||
| DMC Biotechnologies | Venture Capital-Backed | Boulder, CO | ||||
| Amyris (Biotechnology) | Private Equity-Backed | Emeryville, CA | ||||
| Codexis | Formerly VC-backed | Redwood City, CA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA |
Arzeda Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Arzeda Patents
Arzeda Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026231951-A1 | Engineered cellulolytic polypeptides and methods thereof | Pending | 01-May-2025 | ||
| WO-2026176321-A1 | De novo engineered polypeptides and methods of use thereof | Pending | 18-Feb-2025 | ||
| WO-2026176322-A1 | De novo engineered polypeptides and methods of use thereof | Pending | 18-Feb-2025 | ||
| WO-2026006475-A1 | Compositions and methods for glycosylation of steviol glycosides | Pending | 25-Jun-2024 | ||
| AU-2024283953-A1 | Compositions and methods for producing rebaudioside d and rebaudioside m | Pending | 06-Jun-2023 | C12N15/70 |
Arzeda Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Arzeda Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Synthesis Capital | Venture Capital | Minority | ||
| Fall Line Capital | Venture Capital | Minority | ||
| SilverBlue | Venture Capital | Minority | ||
| Sofinnova Partners | Venture Capital | Minority | ||
| Sucden Ventures | Corporate Venture Capital | Minority |
Arzeda FAQs
-
When was Arzeda founded?
Arzeda was founded in 2008.
-
Where is Arzeda headquartered?
Arzeda is headquartered in Seattle, WA.
-
What is the size of Arzeda?
Arzeda has 66 total employees.
-
What industry is Arzeda in?
Arzeda’s primary industry is Biotechnology.
-
Is Arzeda a private or public company?
Arzeda is a Private company.
-
What is the current valuation of Arzeda?
The current valuation of Arzeda is .
-
What is Arzeda’s current revenue?
The current revenue for Arzeda is .
-
How much funding has Arzeda raised over time?
Arzeda has raised $109M.
-
Who are Arzeda’s investors?
Synthesis Capital, Fall Line Capital, SilverBlue, Sofinnova Partners, and Sucden Ventures are 5 of 24 investors who have invested in Arzeda.
-
Who are Arzeda’s competitors?
Novonesis, DMC Biotechnologies, Amyris (Biotechnology), Codexis, and Editas Medicine are some of the 13 competitors of Arzeda.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
